Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7234292 in Manifest Huntington's Disease (GENERATION HD1 China Expansion)
CTR20200199Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tominersen in Huntington disease (HD), sponsored by Roche. Started Oct 2020; status: terminated.
02
Drugs
tominersen
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on CTR20200199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200199.